

## References - Geographic Atrophy

1. Bird AC, Bressler NM, Bressler SB, et al. An International Classification and Grading System for Age-Related Maculopathy and Age-Related Macular Degeneration. The International ARM Epidemiology Study Group. *Surv Ophthalmol*. 1995;39:367-374.
2. Buch H, Vinding T, Nielsen NV, et al. 14-year incidence progression and visual morbidity of age-related maculopathy: The Copenhagen City Eye Study. *Ophthalmology*. 2005;112:787-798.
3. Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. *Arch Ophthalmol*. 1984;102:1640-1642.
4. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. *Ophthalmology*. 1992;99:933-943.
5. Rudnicka AR, Jarrar Z, Wormald R, et al. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. *Ophthalmology*. 2012;119:571-580.
6. Holz FG, Strauss EC, Schmitz-Valckenberg S, et al. Geographic Atrophy Clinical Features and Potential Therapeutic Approaches. *Ophthalmology*. 2014;121:1079-1091.
7. Hanus J, Zhao F, Wang S. Current Therapeutic Development for Atrophic Age-related Macular Degeneration. *Br J Ophthalmol*. 2016;100(6):744.
8. Srinivas S, Chakravarthy U, et al. Clinical endpoints for the study of geographic atrophy secondary to age-related macular degeneration. *Retina*. 2016;36:1806-1822.
9. Age-Related Eye Disease Study Research Group. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in Age-Related Eye disease Study: AREDS report n° 8. *Arch Ophthalmol*. 2008; 119:1417-1436.
10. Ferris FL III, Wilkinson CP, Bird A, et al. Clinical classification of age-related macular degeneration. *Ophthalmology*. 2013;120:844-851.
11. Gass JDM. Drusen and disciform macular detachment and degeneration. *Arch Ophthalmol*. 1973; 90:206-217.
12. Vingerling JR, Dielmans I, Hofman A, et al. The prevalence of age-related maculopathy in the Rotterdam Study. *Ophthalmology*. 1995;102:205-210.
13. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: Pooled findings from three continents. *Ophthalmology*. 2001;108:697-704.
14. Fraser-Bell S, Wu J, Klein R, et al. Smoking, Alcohol Intake, Estrogen Use, and Age-related Macular Degeneration in Latinos: The Los Angeles Latino Eye Study. *Am J Ophthalmol*. 2006;141:79-87.
15. Rudnicka AR, Kapetanakis VV, Jarrar Z, et al. Incidence of late-stage age-related macular degeneration in American whites: systematic review and meta-analysis. *Am J Ophthalmol*. 2015;160:85-93 e83.
16. Klein R, Klein BE, Knudtson MD, et al. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. *Ophthalmology*. 2007;114:253-262.
17. Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration: A case-control study in the Age-Related Eye Disease Study: AREDS report n°3. *Ophthalmology*. 2000;107:2224-2232.
18. Friedman DS, Katz J, Bressler NM, et al. Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey. *Ophthalmology*. 1999;106:1049-1055.
19. Klein R, Klein BE, Knudtson M, et al. Prevalence of Age-related Macular Degeneration in 4 Racial/Ethnic Groups in the Multi-ethnic Study of Atherosclerosis. *Ophthalmology*. 2006;113:373-380.

21. Klein R, Klein BE, Tomany SC. The Association of Cardiovascular Disease with the Long-term Incidence of Age-Related Maculopathy: The Beaver Dam Eye Study. *Ophthalmology*. 2002;110:1273-1280.
22. Postel EA, Agarwal A, Caldwell J, et al. Complement Factor H Increases Risk for Atrophic Age-Related Macular Degeneration. *Ophthalmology*. 2006;113:1504-1507.
23. Dominiek DG, Cornelia MD, Oostra BA, et al. Complement Component C3 and Risk of Age-Related Macular Degeneration. *Ophthalmology*. 2009;115:474-480.
24. Cameron DJ, Yang Z, et al. HTRA1 variant confer similar risk to Geographic Atrophy and Neovascular Age-Related Macular Degeneration. *Cell Cycle*. 2007;6(9):1122-1125.
25. Majewskij, Schultz DW, Weleber RG, et al. Age-Related Macular Degeneration: a genome scan in extended families. *Am J Hum Genet*. 2003;73:540-550.
26. Abecasis GR, Yashar BM, Zhao Y, et al. Age-related macular degeneration: a high resolution genome scan for susceptibility loci in a population enriched for late-stage disease. *Am J Hum Genet*. 2004;74:482-494.
27. Seddon JM, Ajani UA, Mitchell BD. Familial aggregation of age-related maculopathy. *Am J Ophthalmol*. 1997;123:199-206.
28. Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study Severity Scale for Age-Related Macular Degeneration: Age-Related Eye Disease Study (AREDS) report nº 17. *Arch Ophthalmol*. 2005;123:1484-1498.
29. Klein ML, Ferris FLIII, Armstrong J, et al. (AREDS Research Group). Retinal Precursors and the Development of Geographic Atrophy in Age-Related Macular Degeneration. *Ophthalmology*. 2008;115:1026-1031.
30. Pauleikhoff D, Spital G, Bird AC. A Fluorescein and Indocyanine Green Angiographic Study of Choriocapillaris in Age-related Macular Disease. *Arch Ophthalmol*. 1999;117:1353-1358.
31. Kashani AH. Stem Cell Therapy in Nonneovascular Age-Related Macular Degeneration. *Invest Ophthalmol Vis Sci*. 2016;57(5):ORSFm1-9.
32. Klein ML, Ferris FL 3rd, Armstrong J. Retinal precursors and the development of geographic atrophy in age-related macular degeneration. *Ophthalmology*. 2008;115(6):1026-31.
33. Age-Related Eye Disease Study Research Group. Natural History of Drusenoid Pigment Epithelial Detachment in Age-Related Macular Degeneration: AREDS report nº 28. *Ophthalmology*. 2010;117:489-499.
34. Casswell AG Kohen D, Bird AC. Retinal pigment epithelial detachments in the elderly: classification and outcome. *Br J Ophthalmol*. 1985;69:397-403.
35. Finger RP, Wu Z, Luu CD, et al. Reticular pseudodrusen: a risk factor for geographic atrophy in fellow eyes of individuals with unilateral choroidal neovascularization. *Ophthalmology*. 2014;121:1252-1256.
36. Marsiglia M, Boddu S, Bearely S, et al. Association between geographic atrophy progression and reticular pseudodrusen in eyes with dry age-related macular degeneration. *Invest Ophthalmology Vis Sci*. 2013;54:7362-7369.
37. Kovach JL, Schwartz SG, Agarwal A, et al. The relationship between reticular pseudodrusen and severity of AMD. *Ophthalmology*. 2016;123:921-9236.
38. Lutty G, Grunwald J, Majji AB, et al. Changes in choriocapillaris and retinal pigment epithelium in age-related macular degeneration. *Mol Vis*. 1999;5:35.
39. McLeod DS, Taomoto M, Otsuji T, et al. Quantifying Changes in RPE and Choroidal Vasculature in Eyes with Age-Related Macular Degeneration. *Invest Ophthalmol Vis Sci*. 2002;43:1986-1993.
40. Sparrow JR, Boulton M. Lipofuscin and its role in retinal pathobiology. *Exp Eye Res*. 2005;80:595-606.

41. Curcio CA, Medeiros NE, Milican CL. Photoreceptor Loss in Age-Related Macular Degeneration. *Invest Ophthalmol Vis Sci.* 1996;37:1236-1249.
42. Kim SY, Sadda S, Humayun MS, et al. Morphometric Analysis of the Macula in Eyes With Geographic Atrophy due to Age-Related Macular Degeneration. *Retina.* 2002;22:464-470.
43. Holz FG, Schutt F, Kopitz J, et al. Inhibition of Lysosomal Degradative Functions in RPE Cells by a Retinoid Component of Lipofuscin. *Invest Ophthalmol Vis Sci.* 1999;40:737-743.
44. Beatty S, Koh H, Phil M, et al. The Role of Oxidative Stress in the Pathogenesis of Age-Related Macular Degeneration. *Surv Ophthalmol.* 2000;45:115-134.
45. Rózanowska M, Korytowski W, Rózanowski B, et al. Photoreactivity of Aged Human RPE Melanosomes: A Comparison with Lipofuscin. *Invest Ophthalmol Vis Sci.* 2002;43:2088-2096.
46. Anderson DH, Mullins RF, Hageman GS, et al. A Role for Local Inflammation in the Formation of Drusen in the Aging Eye. *Am J Ophthalmol.* 2002;134:411-431.
47. Coleman H R, Ferris III FL, Chew EY, et al. Age related macular degeneration. *Lancet.* 2008;372(9652):1835-1845.
48. Bischoff P, Speiser P. The role of angiography in age-related macular degeneration. *Klin Monatsbl Augenheilkd.* 1997;210:296-8.
49. Shuman JS, Puliafito CA, Fujimoto JG, et al. *Optical Coherence Tomography of Ocular Diseases.* Second edition. Slack, 2004.
50. Bearely S, Chau FY, Koreishi A, et al. Spectral Domain Coherence Tomography Imaging of Geographic Atrophy Margins. *Ophthalmology.* 2009;116:1762-1769.
51. Fleckenstein M, Issa PC, Holz FG, et al. High-Resolution Spectral Domain-OCT Imaging in Geographic Atrophy Associated with Age-Related Macular Degeneration. *Invest Ophthalmol Vis Sci.* 2008;49(9):4137-4144.
52. Karl G Csaky. What Should We Be Measuring as a Geographic Atrophy Endpoint? AAO Subspecialty Day Retina Sillabus.2015; p154-156.
53. Wu Z, Luu CD, Ayton LN, et al. Optical coherence tomography- defined changes preceding the development of drusen-associated atrophy in age-related macular degeneration. *Ophthalmology.* 2014;121:2415-2422.
54. Ouyang Y, Heussen FM, Hariri A, et al. Optical coherence tomography-based observation of the natural history of drusenoid lesion in eyes with dry age-related macular degeneration. *Ophthalmology.* 2013;120:2656-2665.
55. Delori FC, Dorey CK, Staurenghi G, et al. In Vivo Fluorescence of the Ocular Fundus Exhibits Retinal Pigment Epithelium Lipofuscin Characteristics. *Invest Ophthalmol Vis Sci.* 1995;36:718-729.
56. Sparrow JR, Fishkin N, Zhou J, et al. A2E, a Byproduct of the Visual Cycle. *Vision Res.* 2003;43:2983-2990.
57. Frangieh GT, Green WR, Fine SL. A histopathological Study of Best's Macular Dystrophy. *Arch Ophthalmol.* 1982;100:1115-1121.
58. Sparrow JR, Boulton M. Lipofuscin and its role in retinal pathobiology. *Exp Eye Res.* 2005;80:595-606.
59. Von Ruckmann A, Fitzke FW, Bird AC. Fundus Autofluorescence in Age-Related Macular Disease Imaged with Laser scanning Ophthalmoscope. *Invest Ophthalmol Vis Sci.* 1997;38:478-86.
60. Holz FG, Bellman C, Staudt S, et al. Fundus Autofluorescence and Development of Geographic Atrophy in Age-Related Macular Degeneration. *Invest Ophthalmol Vis Sci.* 2001;42:1051-1056.
61. Schmitz-Valkenberg S, Bültmann S, Dreyhaupy J, et al. Fundus autofluorescence and fundus perimetry in the junctional zone of geographic atrophy in patients with age-related macular degeneration. *Invest Ophthalmol Vis Sci.* 2004;45:4470-4476.
62. Schmitz-Valckenberg S, Bindewald-Wittich A, Dolar-Szczasny J, et al. Fundus Autofluorescence and

Fundus Perimetry in the Junctional Zone of Geographic Atrophy in Patients with Age-Related Macular Degeneration. *Invest Ophthalmol Vis Sci.* 2006;47:2648-2654.

63. Bindewald A, Schmitz-Valckenberg S, Jorzik JJ et al. Classification of abnormal fundus autofluorescence patterns in the junctional zone of geographic atrophy in patients with age related macular degeneration. *Br J Ophthalmol.* 2005;89(7):874-8.
64. Holz FG, Bindewald-Wittich A, Fleckenstein M et al. Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. *Am J Ophthalmol.* 2007;143(3):463-72.
65. Suness JS, Gonzalez-Baron J, Bressler NM, et al. The Development of Choroidal Neovascularization in Eyes with Geographic Atrophy Form of Age-Related Macular Degeneration. *Ophthalmology.* 1999;106:910-919.
66. Suness JS, Margalit E, Bressler NM, et al. The Long-term Natural History of Geographic Atrophy from Age-Related Macular Degeneration: Enlargement of Atrophy and Implications for Interventional Clinical Trials. *Ophthalmology.* 2007;114:271-277.
67. Schatz H, McDonald HR. Atrophic Macular Degeneration. Rate of Spread of Geographic Atrophy and Visual Loss. *Ophthalmology.* 1989;96:1541-1551.
68. Bellmann C, Jorzik J, Spital G, et al. Symmetry of bilateral lesions in geographic atrophy in patients with age-related macular degeneration. *Ophthalmology.* 2002;120:579-584.
69. Klein R, Meuer SM, Knudtson MD, Klein BE. The epidemiology of progression of pure geographic atrophy: the Beaver Dam Eye Study. *Am J Ophthalmol.* 2008;146:692-699.
70. Suness JS, Rubin GS, Broman A, et al. Low luminance Visual Dysfunction as a Predictor of Subsequent Visual Loss From Geographic Atrophy in Age-Related Macular Degeneration. *Ophthalmology.* 2008;115:1480-1488.
71. Maguire P, Vine AK. Geographic Atrophy of Retinal Pigment Epithelium. *Am J Ophthalmol.* 1986;102:621-625.
72. Suness JS, Gonzalez-Baron J, Applegate CA, et al. Enlargement of Atrophy and Visual Acuity Loss in the Geographic Atrophy Form of Age-Related Macular Degeneration. *Ophthalmology.* 1999;106:1768-1779.
73. Suness JS, Applegate CA, Bressler NM, et al. Visual Function Abnormalities and Prognosis in Eyes with Age-Related Geographic Atrophy of the Macula and Good Visual Acuity. *Ophthalmology.* 1997;104(10):1677-1691.
74. Davis MD, Gangnon RE, Lee LY, et al. The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. *Arch Ophthalmol.* 2005;123:1484-1498.
75. Schatz H, McDonald HR. Atrophic macular degeneration. Rate of spread of geographic atrophy and visual loss. *Ophthalmology.* 1989;96:1541-1551.
76. Macular Photocoagulation Study Group. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. *Arch Ophthalmol.* 1997;115:741-747.
77. Coleman H, Chew E. Nutritional Supplementation in Age-Related Macular Degeneration. *Curr Opin Ophthalmol.* 2007;18:220-223.
78. Age-Related Eye Disease Study Research Group. Risk Factors for the Incidence of Advanced Age-Related Macular Degeneration in Age-Related Eye Disease Study: AREDS report nº 23. *Arch Ophthalmol.* 2008;126:1274-1279.
79. Chiu CJ, Milton RC, Klein R et al. Dietary Compound Score and Risk of Age-Related Macular Degeneration in the Age-Related Eye Disease Study. *Ophthalmology.* 2008;116: 939-946.
80. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. *JAMA.* 2013;309:2005-15.
81. Khan JC, Thurlby DA, Shahid H, et al. Smoking and age related macular degeneration: the number

of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. *Br J Ophthalmol*. 2006;90:75-80.

82. Age-Related Eye Disease Study Research Group. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in Age-Related Eye Disease Study: AREDS report n<sup>o</sup> 19. *Ophthalmology*. 2005;112:533-539.
83. Age-Related Macular Degeneration PPP - Updated 2015. AAO Retina/Vitreous PPP Panel, Hoskins Center for Quality Eye Care.
84. Jack LS, Sadiq MA, Do DV, Nguyen QD. Emixustat and Lampalizumab: Potential Therapeutic Options for Geographic Atrophy. *Dev Ophthalmol*. 2016;55:302-9.
85. Mata NL, Lichter JB, Vogel R, et al. Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration. *Retina*. 2013;33:498-507.
86. <http://www.businesswire.com/news/home/20160525006550/en/Acucela-Announces-Top-Line-Results-Phase-2b3-Clinical>
87. Elisa Buschini, Antonio M Fea, Carlo A Lavia, et al. Recent developments in the management of dry age-related macular degeneration. *Clin Ophthalmol*. 2015;9:563-574.
88. Barbosa DT, Mendes TS, Cíntron-Colon HR, et al. Age-related macular degeneration and protective effect of HMG Co-A reductase inhibitors (statins): results from the National Health and Nutrition Examination Survey 2005-2008. *Eye (Lond)*. 2014;28(4):472-80.
89. Gehlbach P, Li T, Hafez E. Statins for age-related macular degeneration. *Cochrane Database Syst Rev*. 2012;(3):CD006927.
90. Parsons CG, Ruitenberg M, Freitag CE, et al. MRZ-99030 - A novel modulator of A $\beta$  aggregation: I - Mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD). *Neuropharmacology*. 2015;92:158-69.
91. <https://www.aao.org/interview/brimonidine-geographic-atrophy>
92. Zhang K, Hopkins JJ, Heier JS, et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. *Proc Natl Acad Sci U S A*. 2011;108:6241-5.
93. AREDS Research Group. Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26. *Arch Ophthalmol*. 2009;127:1168-74.
94. Sangiovanni JP, Agron E, Meleth AD, et al.  $\omega$ -3 Long-chain polyunsaturated fatty acid intake and 12-y incidence of neovascular age-related macular degeneration and central geographic atrophy: AREDS report 30, a prospective cohort study from the Age-Related Eye Disease Study. *Am J Clin Nutr*. 2009;90(6):1601-7.
95. Konstantin Petrukin. New Therapeutic Targets in Atrophic Age-Related Macular Degeneration. *Expert Opin Ther Targets*. 2007;11:625-639.
96. Tanito M, Li F, Elliot MH, et al. Protective effect of TEMPOL derivatives against Light-Induced Retinal Damage in Rats. *Invest Ophthalmol Vis Sci*. 2007;48:1900-1905.
97. Wong WT, Kam W, Cunningham D, et al. Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial. *Invest Ophthalmol Vis Sci*. 2010;51(12):6131-6139.
98. Schwartz SD, Regillo CD, Lam BL, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. *Lancet*. 2015;385(9967):509-516.

[View PDF](#)